Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: A focus on zoledronic acid

Therapeutic Advances in Urology

Volumn 4, Issue 2, 2012, Pages 85-101

  Aapro, Matti ^a   Saad, Fred ^b  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

bisphosphonate; bone metastases; genitourinary cancer; prostate cancer; zoledronic acid

Indexed keywords

ABIRATERONE ACETATE; ALPHA INTERFERON; AMINO TERMINAL TELOPEPTIDE; ANALGESIC AGENT; ANDROGEN; CALCIUM; CLODRONIC ACID; DENOSUMAB; DOCETAXEL; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; PREDNISONE; SUNITINIB; VITAMIN D; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ADVANCED CANCER; ANDROGEN BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BLADDER CANCER; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BONE PAIN; BONE TURNOVER; BREAST CANCER; BRIEF PAIN INVENTORY; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COLORECTAL CANCER; CONSERVATIVE TREATMENT; DENTAL PROCEDURE; DISEASE FREE SURVIVAL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GAMMA DELTA T LYMPHOCYTE; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY FUNCTION; LONG TERM CARE; LOW DRUG DOSE; LUNG CANCER; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; MYALGIA; OVARY CANCER; OVERALL SURVIVAL; PAIN ASSESSMENT; PATHOLOGIC FRACTURE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; UROGENITAL TRACT CANCER; VISCERAL METASTASIS; VISUAL ANALOG SCALE; VITAMIN SUPPLEMENTATION;

EID: 84859119876     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287212441234     Document Type: Review

References (116)

1. Aapro M. Abrahamsson P.A. Body J.J. Coleman R.E. Colomer R. Costa L. (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19: 420–432.
2. Aapro M. Launay-Vacher V. (2011) Importance of monitoring renal function in patients with cancer. Cancer Treat Rev [Epub ahead of print].
3. Abrahamsson P.A. Ostri P. Andersen M. Kruger Hagen E. (2008) Nordic observational study evaluating safety and analgesic consumption in patients with advanced cancer under zoledronic acid (ZOMETA®) treatment: NOSAZ–interim analysis. Poster session presented at: 23rd Annual EAU Congress, 26–29 March 2008, Milan, Italy. Abstract 645.
4. Amgen Europe B.V. (2010) Prolia [summary of product characteristics]. Amgen Europe B.V.: Breda, The Netherlands.
5. Amgen Inc. (2010) Xgeva (denosumab) injection [package insert]. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125320s007lbl.pdf. Amgen Inc.: Thousand Oaks, CA.
6. Amgen Inc. (2011) Xgeva (denosumab) granted marketing authorization in the European Union [press release]. Available at: http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1585714. Amgen Inc.: Thousand Oaks, CA.
7. Anand A. Scher H.I. Beer T.M. Higano C.S. Danila D.C. Taplin M. (2010) Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naive patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100. J Clin Oncol 28(15 Suppl.): 353s. Abstract 4546.
8. Aus G. Abbou C.C. Bolla M. Heidenreich A. Schmid H.P. van Poppel H. (2005) EAU guidelines on prostate cancer. Eur Urol 48: 546–551.
9. Babjuk M. Oosterlinck W. Sylvester R. Kaasinen E. Bohle A. Palou-Redorta J. (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59: 997–1008.
10. Berg A. Berner A. Lilleby W. Bruland O.S. Fossa S.D. Nesland J.M. (2007) Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int J Cancer 120: 1603–1609.
11. Bhoopalam N. Campbell S.C. Moritz T. Broderick W.R. Iyer P. Arcenas A.G. (2009) Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol 182: 2257–2264.
12. Body J.-J. Cook R. Costa L. Brown J.E. Terpos E. Saad F. (2009) Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumors and poor prognostic features. Poster session presented at: The IX International Meeting on Cancer Induced Bone Disease, 28–31 October 2009, Arlington, VA. Poster 71.
13. Boissier S. Ferreras M. Peyruchaud O. Magnetto S. Ebetino F.H. Colombel M. (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60: 2949–2954.
14. Boyle W.J. Simonet W.S. Lacey D.L. (2003) Osteoclast differentiation and activation. Nature 423: 337–342.
15. British Association of Urological Surgeons. (2005) Metastatic Prostate Cancer Guidelines. London, UK: The British Association of Urological Surgeons. http://www.echurology.co.uk/baus.html.
16. Brown J.E. Cook R.J. Major P. Lipton A. Saad F. Smith M. (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97: 59–69.
17. Brown J.E. Lipton A. Cook R.J. Michaelson M.D. Saad F. (2009) N-telopeptide of type I collagen (NTX) correlates with survival and fractures in patients (pts) with bone metastases from renal cell carcinoma (RCC). Poster session presented at: American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium, 26–28 February 2009, Orlando, FL. Poster A66.
18. Casey R. Gesztesi Z. Rochford J. (2010) Long term zoledronic acid during androgen blockade for prostate cancer. Can J Urol 17: 5170–5177.
19. Choueiri T.K. Duh M.S. Clement J. Brick A.J. Rogers M.J. Kwabi C. (2010) Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int 105: 1247–1254.
20. Clezardin P. Massaia M. (2010) Nitrogen-containing bisphosphonates and cancer immunotherapy. Curr Pharm Des 16: 3007–3014.
21. Clines G.A. Guise T.A. (2008) Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 10: e7.
22. Clyburn R.D. Reid P. Evans C.A. Lefley D.V. Holen I. (2010) Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy. Cancer Chemother Pharmacol 65: 969–978.
23. Coleman R.E. (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27: 165–176.
24. Coleman R.E. Major P. Lipton A. Brown J.E. Lee K.A. Smith M. (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23: 4925–4935.
25. Cook R.J. Coleman R. Brown J. Lipton A. Major P. Hei Y.J. (2006) Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 12: 3361–3367.
26. Costa L. Cook R. Body J.-J. Brown J.E. Terpos E. Saad F. (2009) Zoledronic acid treatment delays disease progression and improves survival in patients with bone metastases from solid tumors and elevated levels of bone resorption. Poster session presented at: The IX International Meeting on Cancer Induced Bone Disease, 28–31 October 2009, Arlington, VA. Poster 50.
27. Coxon J.P. Oades G.M. Kirby R.S. Colston K.W. (2004) Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 94: 164–170.
28. Daniell H.W. Dunn S.R. Ferguson D.W. Lomas G. Niazi Z. Stratte P.T. (2000) Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163: 181–186.
29. Danila D.C. Anand A. Sung C.C. Leversha M. Rathkopf D.E. Morris M.J. (2010) Molecular profiling of circulating tumor cells (CTC) in patients with castrate metastatic prostate cancer (CMPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy. J Clin Oncol 28(15 Suppl.): 375s. Abstract 4635.
30. Danila D.C. Heller G. Gignac G.A. Gonzalez-Espinoza R. Anand A. Tanaka E. (2007) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13: 7053–7058.
31. de Bono J.S. Logothetis C.J. Molina A. Fizazi K. North S. Chu L. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995–2005.
32. Dearnaley D.P. Mason M.D. Parmar M.K. Sanders K. Sydes M.R. (2009a) Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 10: 872–876.
33. Dearnaley D.P. Mason M.D. Parmar M.K. Sanders K. Sydes M.R. (2009b) Survival benefit with oral sodium clodronate in metastatic but not localised prostate cancer: long-term results of MRC PR04 & PR05. Oral session presented at: American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium, 26–28 February 2009, Orlando, FL. Abstract 6.
34. Dieli F. Vermijlen D. Fulfaro F. Caccamo N. Meraviglia S. Cicero G. (2007) Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67: 7450–7457.
35. Donat D.A. Pesic J.M. Tesanovic S.M. Donat D.D. (2006) Low-dose clodronate as adjunctive therapy in prostate cancer patients with painful bone metastases. Ann Oncol 17(Suppl. 9): ix156. Abstract 484.
36. Ernst D.S. Tannock I.F. Winquist E.W. Venner P.M. Reyno L. Moore M.J. (2003) Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21: 3335–3342.
37. Facchini G. Caraglia M. Morabito A. Marra M. Piccirillo M.C. Bochicchio A.M. (2010) Metronomic administration of zoledronic acid and Taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. Cancer Biol Ther 10: 543–548.
38. Fizazi K. Carducci M. Smith M. Damiao R. Brown J. Karsh L. (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377: 813–822.
39. Garcia M. Jemal A. Ward E.M. Center M. Hao Y. Siegel R.L. (2007) Global cancer facts and figures 2007. Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/globalfactsandfigures2007rev2p.pdf. Atlanta, GA: American Cancer Society.
40. Greenspan S.L. Bone H.G. Ettinger M.P. Hanley D.A. Lindsay R. Zanchetta J.R. (2007) Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146: 326–339.
41. Guise T.A. (2008) Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev 34(Suppl. 1): S19–S24.
42. Hatoum H.T. Lin S.J. Guo A. Lipton A. Smith M.R. (2011) Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Curr Med Res Opin 27: 55–62.
43. Hatoum H.T. Lin S.J. Smith M.R. Barghout V. Lipton A. (2008) Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 113: 1438–1445.
44. Heidenreich A. Bolla M. Joniau S. van der Kwast T.H. Matveev V. Mason M.D. (2009) Guidelines on prostate cancer. Available at: http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/Prostate_Cancer.pdf. Arnhem, The Netherlands: European Association of Urology.
45. Heidenreich A. Ohlmann C. Engelmann U.H. (2005) Ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer. Poster session presented at: 2005 American Society of Clinical Oncology Prostate Cancer Symposium, 17–19 February 2005, Orlando, FL.
46. Henry D.H. Costa L. Goldwasser F. Hirsh V. Hungria V. Prausova J. (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29: 1125–1132.
47. Hering F. Rodrigues P.R. Lipay M. (2003) Clodronate for treatment of bone metastases in hormone refractory prostate cancer. Int Braz J Urol 29: 228–233.
48. Hird A.E. Chow E. Ehrlich L. Probyn L. Sinclair E. Yip D. (2008) Rapid improvement in pain and functional level in a patient with metastatic renal cell carcinoma: a case report and review of the literature. J Palliat Med 11: 1156–1161.
49. Hoff A.O. Toth B.B. Altundag K. Johnson M.M. Warneke C.L. Hu M. (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23: 826–836.
50. Israeli R.S. Rosenberg S.J. Saltzstein D.R. Gottesman J.E. Goldstein H.R. Hull G.W. (2007) The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 5: 271–277.
51. Izumi K. Mizokami A. Sugimoto K. Narimoto K. Miwa S. Maeda Y. (2009) Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology 73: 1342–1346.
52. Josson S. Matsuoka Y. Chung L.W. Zhau H.E. Wang R. (2010) Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin Cell Dev Biol 21: 26–32.
53. Kijima T. Fujii Y. Suyama T. Okubo Y. Yamamoto S. Masuda H. (2009) Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int 103: 620–624.
54. Kollermann J. Weikert S. Schostak M. Kempkensteffen C. Kleinschmidt K. Rau T. (2008) Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol 26: 4928–4933.
55. Koul H.K. Koul S. Kumar B. Meacham R.B. Maroni P. (2010) Direct effects of zoledronic acid on hormone-responsive and hormone-refractory prostate cancer cells. Poster session presented at: American Society of Clinical Oncology 2010 Genitourinary Cancers Symposium, 5–7 March 2010, San Francisco, CA. Abstract 184.
56. Launay-Vacher V. Ayllon J. Janus N. Spano J.P. Ray-Coquard I. Gligorov J. (2009a) Drug management of prostate cancer: prevalence and consequences of renal insufficiency. Clin Genitourin Cancer 7(3): E83–E89.
57. Launay-Vacher V. Oudard S. Janus N. Gligorov J. Pourrat X. Rixe O. (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the Renal Insufficiency and Anticancer Medications (IRMA) study. Cancer 110: 1376–1384.
58. Launay-Vacher V. Spano J.P. Janus N. Gligorov J. Ray-Coquard I. Oudard S. (2009b) Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol 70: 124–133.
59. Lee R.J. Stott S.L. Nagrath S. Ulkus L.E. Dahl D.M. Smith M.R. (2009) Analyses of circulating tumor cell (CTC) dynamics and treatment response in prostate cancer using CTC-chip microfluidic device. J Clin Oncol 27(15 Suppl.): 271s. Abstract 5149.
60. Lipton A. Cook R. Saad F. Major P. Garnero P. Terpos E. (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113: 193–201.
61. Lipton A. Seaman J. Zheng M. (2004) Efficacy and safety of zoledronic acid in patients with bone metastases from renal cell carcinoma. Poster session presented at: What Is New in Bisphosphonates? Seventh Workshop on Bisphosphonates–From the Laboratory to the Patient, 24–26 March 2004, Davos, Switzerland. Abstract 28.
62. Lipton A. Small E. Saad F. Gleason D. Gordon D. Smith M. (2002) The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 20(Suppl. 2): 45–54.
63. Lipton A. Zheng M. Seaman J. (2003) Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98: 962–969.
64. Logothetis C. De Bono J.S. Molina A. Basch E.M. Fizazi K. North S.A. (2011) Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): results from the COU-AA-301 phase III study. J Clin Oncol 29(Suppl.): abstract 4520.
65. Meads M.B. Hazlehurst L.A. Dalton W.S. (2008) The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 14: 2519–2526.
66. Mittan D. Lee S. Miller E. Perez R.C. Basler J.W. Bruder J.M. (2002) Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87: 3656–3661.
67. Miwa S. Mizokami A. Konaka H. Izumi K. Nohara T. Namiki M. (2009) A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy. Jpn J Clin Oncol 39: 745-750.
68. Molina A.M. Motzer R.J. (2011) Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist 16(Suppl. 2): 45–50.
69. Morgan C. Lewis P.D. Jones R.M. Bertelli G. Thomas G.A. Leonard R.C. (2007) The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Acta Oncol 46: 669–677.
70. Morgan T.M. Lange P.H. Porter M.P. Lin D.W. Ellis W.J. Gallaher I.S. (2009) Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 15: 677–683.
71. Mulders P.F. Miller K. Tchekmedyian N.S. Chen Y.M. (2007) Long-term reduction in risk of skeletal complications with zoledronic acid in patients with advanced renal cell carcinoma or bladder cancer. Oral session presented at: 22nd Annual EAU Congress, 21–24 March 2007, Berlin, Germany. Abstract 971.
72. Mundy G.R. (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584–593.
73. Naoe M. Ogawa Y. Takeshita K. Morita J. Shichijo T. Fuji K. (2010) Zoledronate stimulates gamma delta T cells in prostate cancer patients. Oncol Res 18: 493–501.
74. National Comprehensive Cancer Network. (2009) NCCN clinical practice guidelines in oncology: prostate cancer, v.2.2009. Available at: http://www.nccn.org. Fort Washington, PA: National Comprehensive Cancer Network, Inc.
75. Neville-Webbe H.L. Rostami-Hodjegan A. Evans C.A. Coleman R.E. Holen I. (2005) Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113: 364–371.
76. Noguchi M. Yahara J. Noda S. (2003) Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 61: 993–998.
77. Norton L. Massague J. (2006) Is cancer a disease of self-seeding? Nat Med 12: 875–878.
78. Novartis Pharmaceuticals Corporation. (2011) Zometa® (zoledronic acid) injection [package insert]. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021386s004lbl.pdf. East Hanover, NJ: Novartis Pharmaceuticals Corporation.
79. Olmos D. Arkenau H.T. Ang J.E. Ledaki I. Attard G. Carden C.P. (2009) Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 20: 27–33.
80. Padalecki S.S. Carreon M.R. Grubbs B. Cui Y. Guise T.A. (2002) Androgen deprivation causes bone loss and increased prostate cancer metastases to bone: prevention by zoledronic acid. Poster session presented at: 24th Annual Meeting of the American Society for Bone and Mineral Research, 20–24 September 2002, San Antonio, TX. Abstract SU072.
81. Paget S. (1889) The distribution of secondary growths in cancer of the breast. Lancet 1: 571–573.
82. Parker C.C. (2005) The role of bisphosphonates in the treatment of prostate cancer. BJU Int 95: 935–938.
83. Planas J. Trilla E. Raventos C. Cecchini L. Orsola A. Salvador C. (2009) Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU Int 104: 1637–1640.
84. Preston D.M. Torrens J.I. Harding P. Howard R.S. Duncan W.E. McLeod D.G. (2002) Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis 5: 304–310.
85. Ripamonti C.I. Maniezzo M. Campa T. Fagnoni E. Brunelli C. Saibene G. (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20: 137–145.
86. Rodrigues P. Hering F. Campagnari J.C. (2004) Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients. Prostate Cancer Prostatic Dis 7: 350–354.
87. Rogers M.J. Gordon S. Benford H.L. Coxon F.P. Luckman S.P. Monkkonen J. (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(12 Suppl.): 2961–2978.
88. Rosen L.S. Gordon D. Tchekmedyian N.S. Yanagihara R. Hirsh V. Krzakowski M. (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100: 2613–2621.
89. Rosen L.S. Gordon D. Tchekmedyian S. Yanagihara R. Hirsh V. Krzakowski M. (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial–the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21: 3150–3157.
90. Rucci N. Teti A. (2010) Osteomimicry: how tumor cells try to deceive the bone. Front Biosci (Schol Ed) 2: 907-915.
91. Ryan C.W. Huo D. Demers L.M. Beer T.M. Lacerna L.V. (2006) Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 176: 972–978.
92. Saad F. (2008) New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat Rev 34: 183-192.
93. Saad F. Eastham J. (2010a) Maintaining bone health in prostate cancer throughout the disease continuum. Semin Oncol 37(Suppl. 1): S30–S37.
94. Saad F. Eastham J.A. (2010b) Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer. Semin Oncol 37(Suppl. 1): S38–S44.
95. Saad F. Gleason D.M. Murray R. Tchekmedyian S. Venner P. Lacombe L. (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94: 1458–1468.
96. Saad F. Gleason D.M. Murray R. Tchekmedyian S. Venner P. Lacombe L. (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879–882.
97. Saad F. Lipton A. (2005) Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int 96: 964–969.
98. Saad F. Lipton A. Cook R. Chen Y.M. Smith M. Coleman R. (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110: 1860–1867.
99. Scher H.I. Heller G. Molina A. Kheoh T.S. Attard G. Moreira J. (2011) Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. Oral session presented at: 2011 ASCO Annual Meeting, 4–8 June 2011, Chicago, IL. Abstract LBA4517.
100. Shiozawa Y. Havens A.M. Pienta K.J. Taichman R.S. (2008) The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 22: 941–950.
101. Small E.J. Smith M.R. Seaman J.J. Petrone S. Kowalski M.O. (2003) Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21: 4277–4284.
102. Smith M.R. (2006) Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res 12: 6315s–6319s.
103. Smith M.R. Cook R.J. Coleman R. Brown J. Lipton A. Major P. (2007) Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 70: 315–319.
104. Smith M.R. Eastham J. Gleason D.M. Shasha D. Tchekmedyian S. Zinner N. (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169: 2008–2012.
105. Smith M.R. Egerdie B. Hernandez Toriz N. Feldman R. Tammela T.L. Saad F. (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361: 745–755.
106. Smith M.R. McGovern F.J. Zietman A.L. Fallon M.A. Hayden D.L. Schoenfeld D.A. (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345: 948–955.
107. Smith M.R. Saad F. Coleman R. Shore N. Fizazi K. Tombal B. (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379: 39–46.
108. Soltau J. Zirrgiebel U. Esser N. Schachtele C. Totzke F. Unger C. (2008) Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res 28(2A): 933–941.
109. Taxel P. Dowsett R. Richter L. Fall P. Klepinger A. Albertsen P. (2010) Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int 106: 1473–1476.
110. Ullen A. Schwarz S. Lennartsson L. Kalkner K.M. Sandstrom P. Costa F. (2009) Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines. Scand J Urol Nephrol 43: 98–103.
111. US National Institutes of Health (2009) RADAR trial–randomized androgen deprivation and radiotherapy. Available at: http://clinicaltrials.gov/ct2/show/NCT00193856.
112. US National Institutes of Health (2011a) Study on prolonging bone metastasis-free survival in men with hormone refractory prostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00286091.
113. US National Institutes of Health (2011b) Zoledronate plus standard therapy compared with placebo plus standard therapy to prevent bone metastases in patients with recurrent prostate cancer that has no symptoms. Available at: http://clinicaltrials.gov/ct2/show/NCT00005073.
114. Weckermann D. Polzer B. Ragg T. Blana A. Schlimok G. Arnholdt H. (2009) Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol 27: 1549–1556.
115. Yuasa T. Sato K. Ashihara E. Takeuchi M. Maita S. Tsuchiya N. (2009) Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunol Immunother 58: 493–502.
116. Zaghloul M.S. Boutrus R. El-Hossieny H. Kader Y.A. El-Attar I. Nazmy M. (2010) A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 15: 382–389.